Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
abstract, American, Anderson, AstraZeneca, Bayesian, BOIN, Center, conference, Dainippon, domain, engineered, enzyme, escalating, Escalation, exploratory, frontline, healthy, heard, ILAP, ilginatinib, imaging, IMproveMF, inhibitory, Interval, ligand, lymphoid, Merck, MHRA, mouse, Myeloproliferative, Nippon, NS, Passport, pathway, PD, pharmacodynamic, queued, receptor, reportedly, Roche, sector, sequence, Shinyaku, Society, SPC, suboptimal, subsidiary, Sumitomo, text, TGF, tolerable, TP, trap, Unitary, variant, venetoclax, virulent, website
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view